The approval reflects FDAs continued openness to innovation in obesity treatment, including small-molecule alternatives to peptide-based drugs, even as the Agency sharpens its focus on how GLP-1 products and their alternatives are marketed
They help regulate blood sugar, reduce inflammation, and improve insulin sensitivity, all of which are critical for metabolic health
Its reasoning is mechanistic: metformin works mainly in the liver and muscle to reduce insulin resistance and lower fasting glucose, while semaglutide acts on GLP-1 receptors to enhance insulin secretion and reduce appetite
Booster injections are administered by trained medical professionals using sterile techniques
The primary target of medications like Semaglutide and one of three receptors activated by Retatrutide
This year, Xtress is flipping the script